CEVEC to launch human CAP-T™ Cell Expression System

| Print |
Thursday, 05 March 2009 08:33 (UTC + 1)


Cevec_logo


CEVEC to launch CAP-T™ Cell System -
Industry’s State of the Art Human Transient Expression Technology


Cologne, Germany, March 5, 2009 / b3c newswire / - CEVEC Pharmaceuticals GmbH, specializing in the development of complex therapeutic proteins using proprietary human cell-based expression systems, introduces novel CAP-T™ transient expression system for fast, serum-free and high yield protein production. CAP-T™ Technology is the logic result of today’s demand towards creating an efficient, integrated platform for transient production of complex biologics.

 

With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.

 

Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”

 

CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.

 

 

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing complex therapeutic proteins with human glycosylation patterns. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules. CEVEC is licensing out its human cell-based expression platform as well as biological product candidates from internal development through partnerships with renowned pharmaceutical and biotech companies.

 


Contact:
CEVEC Pharmaceuticals GmbH
Dr. Rainer Lichtenberger, CEO
Gottfried-Hagen-Str. 62
51105 Köln, Germany
Tel *49 221 46 02 08 10
Fax *49 221 46 02 08 01
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cevec-pharmaceuticals.com